Sugi Predict

Sugi Predict / Compounds / SCHEMBL16514903

SCHEMBL16514903

SCHEMBL16514903

C=CC(=O)Nc1cccc(-c2cccc3cnc(Nc4ccc(NC5CCN(C)CC5)c(F)c4)nc23)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 3/20 0.71
▸ KDR P35968 3/20 0.71
▸ EGFR P00533 6/20 0.68
▸ FGFR2 P21802 3/20 0.62
▸ CDK2 P24941 2/20 0.51
▸ CCNK O75909 1/20 0.51
▸ CCNA2 P20248 1/20 0.51
▸ CDK7 P50613 1/20 0.51
▸ CCNH P51946 1/20 0.51
▸ MNAT1 P51948 1/20 0.51
▸ CDK12 Q9NYV4 1/20 0.51
▸ BTK Q06187 4/20 0.49
▸ JAK3 P52333 2/20 0.49
▸ PTK2 Q05397 1/20 0.47
▸ EHMT2 Q96KQ7 1/20 0.47
▸ EHMT1 Q9H9B1 1/20 0.47
▸ ITK Q08881 1/20 0.47
▸ JAK2 O60674 1/20 0.46
▸ BRD4 O60885 1/20 0.46
▸ CCNT1 O60563 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16513779 0.94 FGFR1 (0.75) FGFR1KDREGFRFGFR2CDK2
SCHEMBL16514477 0.92 FGFR1 (0.64) FGFR1KDREGFRFGFR2CDK2
SCHEMBL16514476 0.92 FGFR2 (0.72) FGFR1KDREGFRFGFR2CDK2
SCHEMBL16514079 0.90 EGFR (0.70) FGFR1KDREGFRFGFR2CDK2
SCHEMBL29848010 0.90 EGFR (0.70) FGFR1KDREGFRFGFR2CDK2
SCHEMBL16514340 0.88 EGFR (0.69) FGFR1KDREGFRFGFR2BTK
SCHEMBL16514856 0.88 EGFR (0.67) FGFR1KDREGFRFGFR2CDK2
SCHEMBL16513862 0.87 EGFR (0.81) FGFR1KDREGFRFGFR2BTK
SCHEMBL29847855 0.87 EGFR (0.81) FGFR1KDREGFRFGFR2BTK
SCHEMBL16513710 0.86 EGFR (0.74) FGFR1KDREGFRFGFR2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105682661-B Certain chemical entities, compositions, and methods 润新生物公司 2020-03-27 — — CN claimed
EP-3035936-B1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA INC (US) 2019-03-13 — — EP claimed
US-9849139-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC. (US) 2017-12-26 — — US claimed
US-20170196881-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY NEUPHARMA, INC. 2017-07-13 — — US claimed
US-9550770-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC. (US) 2017-01-24 — — US claimed
EP-3035936-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NeuPharma, Inc. (US) 2016-06-29 — — EP claimed
US-20150175601-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2015-06-25 — — US claimed
WO-2015027222-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. (US) 2015-02-26 — — WO claimed
US-20260102406-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY NEUPHARMA INC (US) 2026-04-16 — — US disclosed
US-12403145-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC (US) 2025-09-02 — — US disclosed
US-20240197752-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY NEUPHARMA INC 2024-06-20 — — US disclosed
US-11865120-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC. (US) 2024-01-09 — — US disclosed
US-20220354864-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY NEUPHARMA, INC. 2022-11-10 — — US disclosed
CN-109851617-B Chemical entities, compositions, and methods 润新生物公司 2022-08-16 — — CN disclosed
US-20170196881-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY NEUPHARMA, INC. 2017-07-13 — — US disclosed
US-20170050936-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2017-02-23 — — US disclosed
US-9550770-B2 Substituted quinazolines for inhibiting kinase activity NEUPHARMA, INC. (US) 2017-01-24 — — US disclosed
EP-3035936-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NeuPharma, Inc. (US) 2016-06-29 — — EP disclosed
US-20150175601-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2015-06-25 — — US disclosed
WO-2015027222-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. (US) 2015-02-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170196881-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY DCK, ABL1, MAP4K2 FGFR1 1078/4885KDR 950/4885EGFR 518/4885
US-20240197752-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY DCK, ABL1, MAP4K2 FGFR1 1078/4885KDR 950/4885EGFR 518/4885
US-11865120-B2 Substituted quinazolines for inhibiting kinase activity DCK, ABL1, MAP4K2 FGFR1 1078/4885KDR 950/4885EGFR 518/4885
US-20150175601-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS BRAF, PIK3CA, PLK1 FGFR1 441/4885KDR 1405/4885EGFR 272/4885
US-12403145-B2 Substituted quinazolines for inhibiting kinase activity DCK, ABL1, MAP4K2 FGFR1 1078/4885KDR 950/4885EGFR 518/4885
US-20220354864-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY DCK, ABL1, MAP4K2 FGFR1 1078/4885KDR 950/4885EGFR 518/4885
US-20170050936-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CDK2, MAP3K6, MAP3K2 FGFR1 519/4885KDR 720/4885EGFR 555/4885
US-20260102406-A1 SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY BRAF, TTK, MAP4K2 FGFR1 915/4885KDR 627/4885EGFR 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.